A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Conditions
- Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal Adenocarcinoma
- Interventions
- Registration Number
- NCT05152147
- Lead Sponsor
- Jazz Pharmaceuticals
- Brief Summary
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 918
- Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
- Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
- Adequate organ function
- Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)
- Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
- Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
- Known history of or ongoing leptomeningeal disease (LMD)
- Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
- Known active hepatitis
- Any history of human immunodeficiency virus (HIV) infection
- Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
- QTc Fridericia (QTcF) > 470 ms
- Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B Capecitabine Zanidatamab plus physician's choice of CAPOX or FP Arm B Oxaliplatin Zanidatamab plus physician's choice of CAPOX or FP Arm B Cisplatin Zanidatamab plus physician's choice of CAPOX or FP Arm B 5-Fluorouracil Zanidatamab plus physician's choice of CAPOX or FP Arm C Zanidatamab Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP Arm C Tislelizumab Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP Arm C Capecitabine Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP Arm C Oxaliplatin Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP Arm C Cisplatin Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP Arm C 5-Fluorouracil Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP Arm A Trastuzumab Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) Arm A Capecitabine Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) Arm A Oxaliplatin Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) Arm A Cisplatin Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) Arm A 5-Fluorouracil Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) Arm B Zanidatamab Zanidatamab plus physician's choice of CAPOX or FP
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) by BICR Up to 2.5 years The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause
Overall survival Up to 3.5 years The time from randomization to death due to any cause
- Secondary Outcome Measures
Name Time Method Serum concentration of zanidatamab and tislelizumab Up to 2 years Incidence of anti-drug antibodies (ADAs) Up to 2 years Number of patients who develop ADAs
Confirmed objective response rate (ORR) by BICR Up to 2.5 years Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR
Duration of response (DOR) by BICR Up to 2.5 years The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause
PFS per Investigator assessment Up to 2.5 years The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause
Confirmed ORR per Investigator assessment Up to 2.5 years Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator
DOR per Investigator assessment Up to 2.5 years The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause
Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR Up to 2.5 years The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause
Assessment of Contribution of Components based on Overall Survival Up to 3.5 years The time from randomization to death due to any cause
Incidence of adverse events Up to 2 years Number of subjects who experienced adverse events or serious adverse events
Incidence of clinical laboratory abnormalities Up to 2 years Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30) Up to 2.5 years Changes from baseline in the EORTC QLQ-C30 scores
HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25) Up to 2.5 years Changes from baseline in the EORTC QLQ-OG25 scores
HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire Up to 2.5 years Changes from baseline in the EORTC EQ-5D-5L questionnaire scores
Trial Locations
- Locations (313)
Hospital de Gastroenterología Dr Bonorino Udaondo
🇦🇷Buenos Aires, Argentina
Fundación Centro de Medicina Nuclear y Molecular ER
🇦🇷Córdoba, Argentina
Hospital Italiano de Buenos Aires
🇦🇷Buenos Aires, Argentina
Instituto de Investigaciones Metabólicas - IDIM
🇦🇷Ciudad Autónoma de Buenos Aires, Argentina
Centro Médico Privado CEMAIC
🇦🇷Córdoba, Argentina
Centro de Investigación Clínica - Clínica Viedma
🇦🇷Viedma, Argentina
Border Medical Oncology Research Unit
🇦🇺Albury, Australia
Centro de Investigación Pergamino S.A.
🇦🇷Pergamino, Argentina
Centro de Investigaciones Médicas Tucumán
🇦🇷San Miguel De Tucumán, Argentina
Flinders Medical Centre
🇦🇺Bedford Park, Australia
Liverpool Hospital
🇦🇺Liverpool, Australia
Imelda VZW
🇧🇪Bonheiden, Belgium
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
UZ Gent
🇧🇪Gent, Belgium
CHU de Liège
🇧🇪Liège, Belgium
Fundacao Pio XII - Hospital do Amor Amazonia
🇧🇷Porto Velho, Rondonia, Brazil
Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP - PPDS
🇧🇷Riberao Preto, Sao Paolo, Brazil
Centro Integrado de Pesquisa - CIP
🇧🇷Barretos, Brazil
Fundação Pio XII Hospital de Câncer de Barretos
🇧🇷Barretos, Brazil
Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho
🇧🇷Brasília, Brazil
Instituto Do Câncer Do Ceará ICC
🇧🇷Fortaleza, Brazil
Irmandade Da Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
🇧🇷Porto Alegre, Brazil
INCA - Instituto Nacional de Câncer José Alencar G
🇧🇷Rio De Janeiro, Brazil
Instituto de Oncologia de Sorocaba
🇧🇷Sorocaba, Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo
🇧🇷Santo André, Brazil
Fundación Arturo López Pérez (FALP) - PPDS
🇨🇱Providencia, Región-Metropolitana De Santiago, Chile
Corporacion de Beneficencia Osorno
🇨🇱Osorno, Chile
Centro de Estudios Clínicos SAGA SpA
🇨🇱Providencia, Chile
Meditek Ltda
🇨🇱Recoleta, Chile
Sociedad Oncovida S.A
🇨🇱Santiago, Chile
Beijing Chao-Yang Hospital, Capital Medical University
🇨🇳Beijing, China
Icegclinic
🇨🇱Santiago, Chile
Sociedad de Investigaciones Medicas Limitada
🇨🇱Temuco, Chile
BIOCINETIC SpA
🇨🇱Santiago, Chile
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Beijing, China
Beijing Tiantan Hospital, Capital Medical University
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
Beijing Hospital
🇨🇳Beijing, China
Beijing Luhe Hospital, Capital Medical University
🇨🇳Beijing, China
Peking Union Medical College Hospital
🇨🇳Beijing, China
Hunan Cancer Hospital
🇨🇳Changsha, China
Changzhi People's Hospital
🇨🇳Changzhi, China
Sichuan Cancer Hospital & Institute
🇨🇳Chengdu, China
Foshan First People's Hospital
🇨🇳Foshan, China
The First Affiliated Hospital of Fujian Medical University
🇨🇳Fuzhou, China
The Sixth Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, China
Hainan General Hospital
🇨🇳Haikou, China
The First Affiliated Hospital, College of Medicine, Zhejiang University
🇨🇳Hangzhou, China
Second Affiliated Hospital of Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
The Second Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, China
Anhui Provincial Cancer Hospital
🇨🇳Hefei, China
Affiliated Hospital of Inner Mongolia Medical University
🇨🇳Hohhot, China
Yunnan Cancer Hospital
🇨🇳Kunming, China
The First Hospital of Lanzhou University
🇨🇳Lanzhou, China
Gansu Cancer Hospital
🇨🇳Lanzhou, China
The Affiliated Hospital of Qingdao University
🇨🇳Qingdao, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Shanghai 10th People's Hospital
🇨🇳Shanghai, China
Research Site 1
🇨🇳Shanghai, China
Shangrao People's Hospital
🇨🇳Shangrao, China
Shenzehen People's Hospital
🇨🇳Shenzhen, China
Peking University Shenzhen Hospital
🇨🇳Shenzhen, China
Research Site
🇮🇳Jaipur, India
The Fourth Hospital of Hebei Medical University
🇨🇳Shijiazhuang, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
Weihai Municipal Hospital
🇨🇳Weihai, China
Union Hospital Tongji Medical College HuaZhong University of Science and Technology
🇨🇳Wuhan, China
Hubei Cancer Hospital
🇨🇳Wuhan, China
Affiliated Hospital of Jiangnan University
🇨🇳Wuxi, China
First Affiliated Hospital of Xi 'an Jiaotong University
🇨🇳Xi'an, China
The First Affiliated Hospital of Xiamen University
🇨🇳Xiamen, China
Northern Jiangsu People's Hospital
🇨🇳Yangzhou, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Cancer Hospital affiliated to Xinjiang Medical University
🇨🇳Ürümqi, China
Fakultni nemocnice Olomouc
🇨🇿Hradec Králové, Czechia
North Estonia Medical Centre Foundation
🇪🇪Tallinn, Estonia
East Tallinn Central Hospital
🇪🇪Tallinn, Estonia
Sainte-Catherine, Institut du Cancer Avignon Provence
🇫🇷Avignon, France
Hopital Jean Minjoz
🇫🇷Besançon, France
EDOG - Institut Bergonie - PPDS
🇫🇷Bordeaux, France
Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
🇫🇷Grenoble, France
Universite de Bourgogne - Faculte de Medecine - IN
🇫🇷Dijon, France
EDOG Institut de Cancerologie de l'Ouest - PPDS
🇫🇷Nantes, France
EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
🇫🇷Rennes, France
CHRU de Poitiers La Miletrie
🇫🇷Poitiers, France
CHRU de Brest - Hopital Morvan
🇫🇷Saint-Priest-en-Jarez, France
Hôpital de Rangueil
🇫🇷Toulouse, France
Hôpital Saint Antoine
🇫🇷Villejuif, France
LTD TIM, Tbilisi Institute of Medicine
🇬🇪Tbilisi, Georgia
Research Institute of Clinical Medicine
🇬🇪Tbilisi, Georgia
Tbilisi State Medical University's and Ingorokva's University Clinic of High Medical Technologies
🇬🇪Tbilisi, Georgia
High Technology Hospital MedCenter Ltd
🇬🇪Tbilisi, Georgia
Universitaetsklinikum Leipzig
🇩🇪Leipzig, Germany
Institut für Klinisch-Onkologische Forschung
🇩🇪Frankfurt am Main, Hessen, Germany
Klinikum Mutterhaus der Borromäerinnen
🇩🇪Trier, Rheinland-Pfalz, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Aretaieio Hospital of Athens
🇬🇷Athens, Greece
Attikon University General Hospital
🇬🇷Athens, Greece
Metaxa Memorial Cancer Hospital Piraeus Dept. οf Medical Oncology
🇬🇷Peiraias, Attiki, Greece
Universitaetsklinikum Ulm
🇩🇪Ulm, Germany
Agios Loucas Clinic SA
🇬🇷Thessaloniki, Greece
Interbalkan Medical Center of Thessaloniki Oncology Department
🇬🇷Thessaloniki, Greece
Bioclinic Thessaloniki Oncology Department
🇬🇷Thessaloniki, Greece
Clinica Medica Especializada CELAN
🇬🇹Guatemala City, Guatemala
Integra Cancer Institute
🇬🇹Guatemala City, Guatemala
The Bangalore Hospital
🇮🇳Bangalore, India
Artemis Hospital
🇮🇳Gurgaon, India
Centro Medico Integral de Cancerologia CEMIC
🇬🇹Salcaja, Guatemala
All India Institute of Medical Sciences, Bhubaneswar
🇮🇳Bhubaneswar, India
MNJ Institute of Oncology and Regional Cancer Centre
🇮🇳Hyderabad, India
Curie Manavata Cancer Centre
🇮🇳Nashik, India
Indraprastha Apollo Hospitals
🇮🇳New Delhi, India
Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
🇮🇳Patna, India
Deenanath Mangeshkar Hospital and Research Centre
🇮🇳Pune, India
HCG City Cancer Center
🇮🇳Vijayawada, India
St James's Hospital
🇮🇪Dublin, Ireland
Azienda Ospedaliero Universitaria Di Modena Policlinico
🇮🇹Modena, Italy
Centro Ricerche Cliniche Di Verona
🇮🇹Verona, Italy
Gifu University Hospital
🇯🇵Gifu-Shi, Gihu, Japan
Fukui Prefectural Hospital
🇯🇵Fukui-shi, Hukui, Japan
Hyogo Cancer Center
🇯🇵Akashi-shi, Hyôgo, Japan
Gunma Prefectural Cancer Center
🇯🇵Ota-shi, Gunma, Japan
Kobe City Medical Center General Hospital
🇯🇵Kobe-Shi Chuo-Ku, Hyôgo, Japan
Ibaraki Prefectural Central Hospital
🇯🇵Kasama-Shi, Ibaraki, Japan
Kagawa University Hospital
🇯🇵Kita-Gun Miki-Cho, Kagawa, Japan
Kitasato University Hospital
🇯🇵Yokohama-Shi Minami-Ku, Kanagawa, Japan
Kyoto University Hospital
🇯🇵Sakyo-ku, Kyoto-shi, Japan
Kanagawa Cancer Center
🇯🇵Yokohama-Shi Asahi-Ku, Kanagawa, Japan
Osaki Citizen Hospital
🇯🇵Osaki-Shi, Miyagi, Japan
Kumamoto University Hospital - Honjo-Kuhonji Campus A
🇯🇵Chuo-Ku, Kumamoto, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Osaka, Japan
Kurashiki Central Hospital
🇯🇵Kurashiki-Shi, Okayama, Japan
Osaka University Hospital
🇯🇵Suita-Shi, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital
🇯🇵Takatsuki-Shi, Osaka, Japan
Chiba Cancer Center
🇯🇵Chiba-Shi, Tiba, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa-shi, Tiba, Japan
National Cancer Center Hospital
🇯🇵Chuo Ku, Japan
Keio University Hospital
🇯🇵Shinjuku-Ku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka-shi, Japan
Saitama Cancer Center
🇯🇵Ina, Japan
Shikoku Cancer Center
🇯🇵Matsuyama, Japan
Aichi Cancer Center
🇯🇵Nagoya shi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata-shi, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
Hallym University Sacred Heart Hospital
🇰🇷Anyang-si, Korea, Republic of
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
CHA Bundang Medical Center, CHA University
🇰🇷Seongnam-si, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System - PPDS
🇰🇷Seoul, Korea, Republic of
Gangnam Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Pulau Pinang
🇲🇾George Town, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Sarawak General Hospital
🇲🇾Kuching, Malaysia
National Cancer Institute ( Institut Kanser Negara)
🇲🇾Putrajaya, Malaysia
Pantai Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
Health Pharma Professional Research S.A de C.V.
🇲🇽Mexico City, Mexico
Cryptex Investigación Clínica, S.A. de C.V.
🇲🇽Mexico City, Mexico
Clinstile, S.A. de C.V.
🇲🇽Mexico City, Mexico
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca, Mexico
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Leids Universitair Medisch Centrum
🇳🇱Leiden, Netherlands
Centrum Medyczne Poznan - PRATIA - PPDS
🇵🇱Skórzewo, Poland
ETZ-Elisabeth
🇳🇱Tilburg, Netherlands
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
🇵🇱Łódź, Poland
Hospital Garcia de Orta
🇵🇹Almada, Portugal
Centro Hospitalar E Universitário de Coimbra EPE
🇵🇹Coimbra, Portugal
Hospital Beatriz Angelo
🇵🇹Loures, Portugal
Unidade Local de Saúde de Matosinhos SA
🇵🇹Matosinhos, Portugal
Centro Hospitalar do Porto EPE
🇵🇹Porto, Portugal
Fundeni Clinical Institute
🇷🇴București, Romania
Prof Dr I Chiricuta Institute of Oncology - PPDS
🇷🇴Cluj-Napoca, Romania
Cardiomed SRL
🇷🇴Cluj-Napoca, Romania
Oncology Center Sfantul Nectarie
🇷🇴Craiova, Romania
Institutul Regional de Oncologie Iasi
🇷🇴Iasi, Romania
Military Medical Academy
🇷🇸Belgrade, Serbia
Institute for Oncology and Radiology of Serbia - PPDS
🇷🇸Belgrade, Serbia
University Clinical Center Nis
🇷🇸Niš, Serbia
Oncocare Cancer Centre
🇸🇬Singapore, Singapore
Curie Oncology
🇸🇬Singapore, Singapore
Oncology Institute of Vojvodina
🇷🇸Sremska Kamenica, Serbia
Cape Town Oncology Trials
🇿🇦Cape Town, South Africa
Southern Cross Research South Africa (PTY) LTD
🇿🇦Mogale City, South Africa
University of Pretoria
🇿🇦Pretoria, South Africa
Wilgers Oncology Centre
🇿🇦Pretoria, South Africa
Corporacio Sanitaria Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario Vall d'Hebron - PPDS
🇪🇸Barcelona, Spain
Hospital Universitario Germans Trias i Pujol
🇪🇸Badalona, Spain
Hospital Universitari de Girona Dr Josep Trueta
🇪🇸Girona, Spain
Institut Català d'Oncologia (Hospital Duran y Reynals)
🇪🇸L'Hospitalet de Llobregat, Spain
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario La Paz - PPDS
🇪🇸Madrid, Spain
Hospital Regional Universitario de Malaga - Hospital General
🇪🇸Málaga, Spain
Complejo Asistencial Universitario de Salamanca - H. Clinico
🇪🇸Salamanca, Spain
Hospital Universitario Marques de Valdecilla
🇪🇸Santander, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Chi Mei Medical Center
🇨🇳Tainan, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Siriraj Hospital Mahidol University
🇹🇭Bangkok Noi, Thailand
Phramongkutklao Hospital
🇹🇭Bangkok, Thailand
Songklanagarind Hospital
🇹🇭Hat Yai, Thailand
Srinagarind Hospital, Khon Kaen University
🇹🇭Khon Kaen, Thailand
Chulaborn Hospital
🇹🇭Lak Si, Thailand
Naresuan University
🇹🇭Phitsanulok, Thailand
Istanbul Universitesi Cerrahpasa Tip Fakultesi
🇹🇷Fatih, Istanbul, Turkey
Akdeniz University Medical Faculty
🇹🇷Antalya, Turkey
Antalya Yaşam Onkoloji Merkezi
🇹🇷Antalya, Turkey
Research site
🇹🇷Çankaya, Turkey
Uludag Universites Tip Fakultesi Hastanesi
🇹🇷Bursa, Turkey
Dicle University Medical Faculty
🇹🇷Diyarbakir, Turkey
Trakya University Medical Faculty
🇹🇷Edirne, Turkey
Acibadem Maslak Hospital
🇹🇷Sariyer, Turkey
Dokuz Eylul Universitesi
🇹🇷Izmir, Turkey
Medical Park Trabzon Yildizli
🇹🇷Trabzon, Turkey
Acibadem Adana Hospital
🇹🇷Seyhan, Turkey
Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council - PPDS
🇺🇦Dnipropetrovsk, Ukraine
Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital
🇹🇷Yenimahalle, Turkey
Medical Center of Limited Liability Company "Medical center "VERUM EXPERT"
🇺🇦Kyiv, Ukraine
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council
🇺🇦Kryvyi Rih, Ukraine
Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima
🇺🇦Kyiv, Ukraine
Communal Nonprofit Enterprise Kyiv City Clinical Oncological Center
🇺🇦Kyiv, Ukraine
SI "National Institute of Surgery and Transplantology n.a. O.O. Shalimov " of NAMS of Ukraine
🇺🇦Kyiv, Ukraine
The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council
🇺🇦Lutsk, Ukraine
Daycare Facility of Dispensary-Polyclinic Department
🇺🇦Odesa, Ukraine
Bristol Haematology and Oncology Centre
🇬🇧Bristol, United Kingdom
Western General Hospital Edinburgh - PPDS
🇬🇧Edinburgh, United Kingdom
St James University Hospital
🇬🇧Leeds, United Kingdom
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital - London
🇬🇧London, United Kingdom
Royal Marsden Hospital - Surrey
🇬🇧London, United Kingdom
Mount Vernon Hospital
🇬🇧Northwood, United Kingdom
Edith Cavell Hospital
🇬🇧Peterborough, United Kingdom
Weston Park Cancer Centre
🇬🇧Sheffield, United Kingdom
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
Shandong Cancer Hospital
🇨🇳Jinan, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Jinan Central Hospital
🇨🇳Jinan, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, China
Ruijin hospital Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
Fudan University Affiliated Zhongshan Hospital
🇨🇳Shanghai, China
Shanghai General Hospital
🇨🇳Shanghai, China
Research Site 2
🇨🇳Shanghai, China
Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing, China
Shanghai East Hospital
🇨🇳Shanghai, China
The First Hospital of China Medical University
🇨🇳Shenyang, China
Liaoning Cancer Hospital & Institute
🇨🇳Shenyang, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, China
Grupo Medico Angeles
🇬🇹Guatemala City, Guatemala
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
🇯🇵Tokyo, Japan
Catharina Hospital
🇳🇱Eindhoven, Netherlands
Clinical Hospital Center Bezanijska Kosa
🇷🇸Belgrade, Serbia
Hospital Universitario Dr. Jose Eleuterio González
🇲🇽Monterrey, Mexico
Onco Clinic Consult SA
🇷🇴Craiova, Romania
Vajira Hospital
🇹🇭Bangkok, Thailand
Kindai University Hospital
🇯🇵Osaka-sayama, Japan
Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
🇵🇱Warszawa, Poland
Hospital Senhora da Oliveira - Guimaraes, E.P.E
🇵🇹Guimarães, Portugal
National Cancer Center Singapore
🇸🇬Singapore, Singapore
UZ Leuven
🇧🇪Leuven, Belgium
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
🇵🇹Porto, Portugal
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
🇵🇹Lisboa, Portugal
Medisprof SRL
🇷🇴Cluj-Napoca, Romania
University Clinical Center of Serbia - PPDS
🇷🇸Belgrade, Serbia
Communal Non-profit Enterprise Regional Center of Oncology
🇺🇦Kharkiv, Ukraine
China Medical University Hospital
🇨🇳Taichung, Taiwan
The Tonghua Central Hospital
🇨🇳Tonghua, China
Ospedale Policlinico San Martino
🇮🇹Genova, Italy
Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
🇮🇹Bologna, Italy
Fondazione del Piemonte per l'Oncologia (IRCCS)
🇮🇹Candiolo, Italy
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
🇮🇹Meldola, Italy
Ospedale San Raffaele S.r.l. - PPDS
🇮🇹Milano, Italy
Istituto Nazionale Dei Tumori
🇮🇹Milano, Italy
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda
🇮🇹Milano, Italy
Arcispedale Santa Maria Nuova
🇮🇹Reggio Emilia, Italy
Fondazione Policlinico Universitario A Gemelli
🇮🇹Rome, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino
🇮🇹Torino, Italy
Azienda ULSS 8 "Berica" - Ospedale San Bortolo
🇮🇹Vicenza, Italy
Hacettepe Universitesi Kanser Enstitusu
🇹🇷Ankara, Turkey
Centre Léon Berard
🇫🇷Lyon, France
CEDOES Diagnostico E Pesquisa
🇧🇷Praia Do Canto, Vitoria, Brazil
ONCOSITE Centro de Pesquisa Clínica Em Oncologia
🇧🇷Ijuí, Brazil
Cenantron - Centro Avancado de Tratamento Oncologico Ltda
🇧🇷Belo Horizonte, Brazil
Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Hospital Nossa Senhora Da Conceição
🇧🇷Porto Alegre, Brazil
Instituto do Cancer do Estado de São Paulo ICESP
🇧🇷São Paulo, Brazil
Austin Health
🇦🇺Heidelberg, Australia
Princess Margaret Cancer Centre
🇨🇦Toronto, Canada
Fiona Stanley Hospital
🇦🇺Murdoch, Australia
Instituto D Or de Pesquisa e Ensino - Hospital Sao Rafael - PPDS
🇧🇷Salvador, Bahia, Brazil
Fujian Cancer Hospital
🇨🇳Fuzhou, China
Changzhou First People's Hospital
🇨🇳Changzhou, China
The First Affiliated Hospital of Bengbu Medical College
🇨🇳Bengbu, China
Related News
Zymeworks Outlines Strategic Priorities and Outlook for
FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer
- Prev
- 1
- Next